Novel targets for inflammatory bowel disease therapeutics

Current Gastroenterology Reports

Volumn 15, Issue 2, 2013, Pages

  Löwenberg, Mark ^a   D'Haens, Geert ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Clinical Trials   (Netherlands)

Author keywords

Adhesion molecule blockers; Anti tumor necrosis factor (TNF) antibodies; Biologicals; Crohn's disease (CD); Inflammatory bowel disease (IBD); Small molecules; Tofacitinib; Ulcerative colitis (UC); Ustekinumab; Vedolizumab

Indexed keywords

ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; LAQUINIMOD; NATALIZUMAB; PF 547659; PLACEBO; TOFACITINIB; USTEKINUMAB; VEDOLIZUMAB; VERCIRNON;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ULCERATIVE COLITIS;

EID: 84872094478     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0311-3     Document Type: Article

References (28)

1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9. (Pubitemid 34621118)
3. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33.
4. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-7.
5. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76. (Pubitemid 41770166)
6. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.
7. Rutgeerts P, van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-11.
8. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.
9. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-38. (Pubitemid 47080387)
10. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of 12 certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-18. (Pubitemid 41242673)
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-50. (Pubitemid 47080388)
12. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688-95.
13. Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas JL, MrossM, D'Haens G, Mitchev K, Ernault E, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY,Marteau P, Colombel JF: Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut. 2012. doi:10.1136/gutjnl-2012-302262.
14. Behm BW, Bickston SJ: Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;CD006893. doi:10.1002/14651858.CD006893. (Pubitemid 351807740)
15. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, SandbornWJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-53. (Pubitemid 351783447)
16. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007;13:26-8. (Pubitemid 46067378)
17. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-10. (Pubitemid 44594033)
18. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-28.
19. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-25. (Pubitemid 41565956)
20. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-83. (Pubitemid 46695722)
21. Bloomgren G, Richman S, Hotermans C, SubramanyamM, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80.
22. Parikh A, Leach T,Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18:1470-9.
23. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-507. (Pubitemid 41007865)
24. Feagan BG, Greenberg GR,Wild G, Fedorak RN, Pare P,McDonald JW, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370-7.
25. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis - the kinase inhibitors. Bull NYU Hosp Jt Dis. 2011;69:233-7.
26. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-24.
27. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000-9.
28. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61:918-32.